Report Company Directory

REGENCY TRUST LTD

REGENEREX PHARMA INC

Regeneron Pharmaceuticals Inc.

• Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 by GlobeNewsWire
• Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization by GlobeNewsWire
• Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) by GlobeNewsWire
• Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial by GlobeNewsWire
• Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color by GlobeNewsWire
• Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist by GlobeNewsWire
• Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass by GlobeNewsWire
• Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing by GlobeNewsWire
• Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials by GlobeNewsWire
• Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma by GlobeNewsWire

Regeneus

• Regeneus Ltd: 1 director by SmartInsider
• Monthly LMI Update Independent Investment Research by Independent Investment Research
• Feasibility Study Results in December to be a Catalyst for this Junior by Fundamental Research
• Regeneus - Several interested parties in Japan by Edison Investment Research
• Regeneus - Positive STEP data and Japan patent grant by Edison Investment Research
• Regeneus - Preparing for a clinical licence deal in Japan by Edison Investment Research
• Regeneus - Preparing for a clinical licence deal in Japan by Edison Investment Research
• Regeneus - Positive STEP data and Japan patent grant by Edison Investment Research
• Japan collaboration validates Progenza by Edison Investment Research
• Ford Equity International Rating and Forecast Report by Ford Equity Research

Regenicin Inc.